Department of psychiatry
Esketamine (Spravato) was approved by Health Canada for treatment resistant depression in 2020. It is the first medication in its class available for this indication. This presentation will review the potenital role of esketamine in the treatment of major depressive disorder.
As a result of attending this session, participants will be able to:
08:30 - 10:35
|Plenary - 1||Esketamine: A game changer in depression treatment?|
11:00 - 12:00
|What really works in treatment-resistant depression? - Daniel Zigman||What really works in treatment-resistant depression?|